1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Peripheral T-cell Lymphomas (PTCL): new trials by email Literature Review of Peripheral T-cell Lymphomas (PTCL) trials Research Report on Peripheral T-cell Lymphomas (PTCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine (Dose level 21), Lenalidomide and Gemcitabine (Dose level 31) - Peripheral T-cell Lymphomas (PTCL) | Phase 1 / Phase 2 | Terminated | National Health Research Institutes, Taiwan | 12 | 2022-06-15 | 2024-07-08 |
Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Gemcitabine (1) · Lenalidomide (1)
National Health Research Institutes, Taiwan (1)
Taiwan (1)
Tsang-Wu Liu (1)